Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zr-89 Cimzia PET Imaging Rheumatoid Arthritis
Sponsor: Robert Flavell, MD, PhD
Summary
This is a single center exploratory imaging study investigating the initial application of zirconium-89 Deferoxamine B Certolizumab pegol (89Zr-DFO-CZP) PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.
Official title: Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2018-10-01
Completion Date
2029-03-31
Last Updated
2026-05-04
Healthy Volunteers
No
Conditions
Interventions
89Zr-DFO-CZP
89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
Locations (1)
University of California, San Francisco
San Francisco, California, United States